McAdam, Karen
Peterborough City Hospital
4 papers on CoChatORCID 0000-0002-5545-2982
Most cited papers
- Verified
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 177
- Verified
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
Dalgleish, A. G., Stebbing, J., Adamson, D. J., Arif, S. S., Bidoli, P., Chang, D., Cheeseman, S., Diaz-Beveridge, R., Fernandez-Martos, C., Glynne-Jones, R., et al. (2016) · British Journal of Cancer
Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment
Cited by 75
- Verified
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., et al. (2024) · Nature
PARP inhibition in cancer therapyBreast Cancer Treatment Studies
Cited by 53
- Verified
PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer.
Drewett, L., Lucey, R., Pinilla, K. A., Grybowicz, L., Wulff, J., Dayimu, A., Demiris, N., Vallier, A.-L., Qian, W., Machin, A., et al. (2022) · Journal of Clinical Oncology
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 6
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free